INTRODUCTION Erlotinib is an inhibitor of human epidermal growth factor approved for treating non-small cell lung cancer. The aim of this prospective observational study was to determine the prevalence of adverse cutaneous reactions caused by erlotinib and assess the management of such effects. METHODS Eleven patients with lung cancer and 1 with ovarian cancer received erlotinib at a dose of ...

OBJECTIVE According to the basic role of drug side effects in selection of an appropriate drug, patient compliance and the quality of life in epileptic patients, and forasmuch as new drugs with unknown side effect have been introduced, necessity of this research is explained. This study was conducted to evaluate the incidence and clinical characteristics of anti epileptic drug (AED) related adv...

Kaposi's varicelliform eruption (eczema herpeticum) is the name given to a distinct cutaneous eruption caused by herpes simplex and certain other viruses that infect persons with preexisting dermatosis. Most commonly it is associated with atopic dermatitis. We report a case of a three-year-old atopic child who presented with extensive vesicular eruption suggestive of Kaposi's varicelliform erup...

Introduction: Sarcoidosis is a systemic non-infectious granulomatous disorder which exhibits various specific and non-specific cutaneous manifestations. Erythema nodosum-like eruption is a rare specific lesion associated with sarcoidosis, which histologically shows noncaseating epithelioid granuloma. It is suggested that this type is frequently associated with ocular sarcoidosis. Main observati...

BACKGROUND: Cetuximab and erlotinib, epidermal growth factor receptor inhibitors, often cause peculiar adverse cutaneous reactions. OBJECTIVES: Our aim was to evaluate adverse cutaneous reactions and their management in patients undergoing treatment with cetuximab and erlotinib. PATIENTS AND METHODS: Between March/2005 and September/2009, we observed 14 patients with a mean age of 59.6 years un...

Cutaneous drug eruptions are one of the most common types of adverse reaction to drug therapy, with an overall incidence rate of 2–3% in hospitalised patients.1–3 Almost any medicine can induce skin reactions, and certain drug classes, such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and antiepileptics, have drug eruption rates approaching 1–5%.4 Although most drug-related sk...

PURPOSE Immunotherapy has experienced impressive progress in cancer treatment. Antibodies against PD-1 improved survival in different types of cancer including melanoma. They are generally well tolerated. However, skin toxicities including pruritus, rashes, and vitiligo are reported. Although frequent, they have not been characterized further yet. In this analysis, we aimed to systematically as...

Fixed Drug Eruption (FDE) is classified as cutaneous drug reaction which recurs in the same locations upon systemic administration of the same drug. Vesicles and bullae may sometimes be found, and in some cases even these are confused with Stevens Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). A male patient, 62 years old, developed FDE with the use of ornidazole. On physical exami...

Fixed drug eruption (FDE) is a unique type of cutaneous drug reaction that typically recurs in the identical locations on re-exposure to the attributed drug. FDE is characterized by the appearance of a single or multiple sharply demarcated violaceous erythematous plaques which heal with residual hyperpigmentation. A 27-year-old woman presented with multiple dark patches over her eyelids, mouth,...